AKT1 and neoplasm: The rescue experiments indicated that an AKT activator SC79 can significantly reverse isorhamnetin’s anti-tumor effects on GBC cells by inhibiting proliferation and metastasis, inducing apoptosis and G2/M cycle arrest, and downregulating PI3K/AKT signaling pathways in vitro.